A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
Launched by JANSSEN-ORTHO LLC · Sep 13, 2005
Trial Information
Current as of April 27, 2025
Completed
Keywords
ClinConnect Summary
Amotriptan malate (AXERT®) is approved for use in the treatment of acute migraine headache with or without aura in adults. Other studies have shown that almotriptan is effective and well tolerated in adults. Migraines in teenagers/adolescents are very similar to migraines in adults, except that the duration is usually less in adolescents (they last 1 to 24 hours in adolescents). This study will evaluate the usefulness of almotriptan malate (AXERT®) in treating acute migraine headaches in adolescents. This is a randomized, double-blind, parallel-group, and placebo-controlled study. During a ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of migraine with or without aura for \> 1 year
- • Average of 1 to 6 moderate or severe migraines per month for 2 months before entering the study
- • Untreated migraines lasting at least 4 hours
- • At least 24 hours between migraines
- • Able to tell the difference between migraines and other types of headache
- • If female, using birth control
- Exclusion Criteria:
- • Chronic tension or cluster headache
- • Prolonged aura
- • Specific types of migraine
- • \> 6 nonmigraine headaches per month
- • High blood pressure for the age
- • Medical history with specific significant conditions affecting the liver, kidney, heart or other body systems
- • Conditions that might affect the way the body absorbs or processes a drug
- • Positive blood tests for Hepatitis B or C
- • Recent head or neck injury
- • Body weight outside given parameters
- • Unable to take sumatriptan
- • Abusing drugs or alcohol
- • Pregnant or breast-feeding
- • Use of antimigraine medication that might interfere with the study, of antimigraine medication for \< 2 weeks, of lithium or monoamine oxidase inhibitors in past 2 weeks, of an investigational drug within 2 months
- • Refuse to abstain from taking medicine with ergotamine or any other drug like almotriptan within 48 hours before and 24 hours after taking study medication, or drugs containing opiates or antivomiting medicine within 48 hours before and 2 hours after taking study medication
- • Use of simple pain medicines within 24 hours (like aspirin)
About Janssen Ortho Llc
Janssen-Ortho LLC, a subsidiary of Johnson & Johnson, is a global healthcare leader dedicated to addressing unmet medical needs through innovative pharmaceutical research and development. Specializing in a diverse range of therapeutic areas, including oncology, immunology, and neuroscience, the organization is committed to advancing patient care and improving health outcomes. With a strong emphasis on clinical trials, Janssen-Ortho LLC collaborates with healthcare professionals and institutions to generate robust clinical evidence that supports the efficacy and safety of its products, ultimately striving to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Janssen Ortho LLC Clinical Trial
Study Director
Janssen-Ortho LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials